DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE
Pre-Launchdolutegravir lamivudine tenofovir alafenamide
NDATABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing dolutegravir (integrase strand transfer inhibitor), lamivudine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor) for HIV treatment. The combination works through multiple mechanisms to suppress viral replication by inhibiting key enzymes in the HIV lifecycle. This represents a once-daily, single-tablet regimen for treatment-naive and treatment-experienced HIV patients.
Pre-Launch
As a pre-launch product, this represents opportunity to build infrastructure for a new market entry in the competitive HIV space; commercial teams will be establishing market positioning and launch planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch product offers opportunity to build commercial momentum for Cipla's entry into the premium HIV treatment market with a differentiated pricing and access strategy. This is a launch-phase opportunity suitable for professionals seeking to establish market presence in a mature but continually evolving therapeutic area.
Brand ManagerCommercial Lead
Worked on DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.